Abeona Therapeutics Inc. (NASDAQ: ABEO) announced today updated clinical data from the Phase 1/2 trial for ABO-102 (AAV-SGSH), the company’s ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT MeetingMay 18, 2018 9:25 AM Abeona Therapeutics (ABEO) Updates Clinical Data from Phase 1/2 Trial for EB-101 Gene Therapy in Epidermolysis BullosaMay 17, 2018 9:21 AM